<DOC>
	<DOC>NCT01660334</DOC>
	<brief_summary>To collect the efficacy and safety information of voriconazole related to their appropriate use in daily practice.</brief_summary>
	<brief_title>Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Male or Female patients who are prescribed voriconazole (VFEND) for deep mycosis on Scedosporisis. Subject who have been prescribed voriconazole (VFEND) for deep mycosis on Aspergillus, Candidasis,Cryptococcal infections not involving Scedosporisis.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Systemic Mycosis</keyword>
	<keyword>Scedosporium infection</keyword>
	<keyword>Scedosporisis</keyword>
	<keyword>Japanese</keyword>
	<keyword>voriconazole</keyword>
	<keyword>VFEND</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan.</keyword>
</DOC>